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We previously reported the production of a fused snake neurotoxin composed of protein A and erabutoxin a in E. coli [1]. The hybrid had much 
lower toxicity and affinity for the acetylcholine nicotinic receptor than natural erabutoxin. By treating the hybrid with cyanogen bromide we 
generated a toxin which was purified in a single step by RP-HPLC. This compound, produced in a good yield, recovered all properties of native 
erabutoxin a, implying that the lower toxic activities of the hybrid were due to the bulky protein A and not to an incorrect folding of the toxin. 
This work serves as a basis for future studies of toxin-receptor interactions using engineered toxin mutants. 
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1. INTRODUCTION 
Previously, we reported on the direct expression i E. 
coli of a heterologous protein composed of protein A 
coupled to a snake neurotoxin. The fused toxin was 
capable of binding to the acetylcholine icotinic recep- 
tor (AcChoR) but with a much lower affinity than 
native toxin [1], making the hybrid inappropriate for 
detailed studies of toxin-receptor interactions. The 
hybrid was also less toxic in vivo [1]. Possibly, the non- 
native biological properties of the fused toxin were due 
to an incorrect folding of the toxin and/or to a steric 
hindrance by the bulky protein A. This unclear situa- 
tion prompted us to delete the protein A moiety from 
the toxin. Appropriate mutations inthe plasmid [1] had 
located a methionine at position -1 of the toxin se- 
quence. In the present paper we describe (i) the cleavage 
of the hybrid with cyanogen bromide; (ii) the purifica- 
tion of the generated toxin and (iii) the physicochemical 
and biological properties of this first recombinant 
snake toxin. 
2. MATERIALS AND METHODS 
2.1. Materials 
Amino acid composition analysis was performed using an 
automatic model 130 A amino acid analyzer following total acid 
hydrolysis (6 N HCI, I10°C, 24 h) and subsequent precolumn 
phenylisothiocyanate derivatization using the on-line model 420 A 
derivatizer; sequencing was performed on a pulsed liquid 477 A pro- 
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tein sequencer, and the resulting phenylthiohydantoin derivatives of 
amino acids were analysed by HPLC using the on-line model 120 A 
analyzer (Applied Biosystems, Foster City, CA, USA). Dichroic spec- 
tra were recorded at 22°C, using a CD III Jobin-Yvon dichrograph. 
2.2. Expression and purification of the fusion protein 
The fusion protein expressed in E. coli was purified using a one- 
step affinity chromatography on immobilized neurotoxin-specific 
monoclonal antibody [1]. 
2.3. Cyanogen bromide cleavage 
In a typical experiment, 3 mg of fusion protein were incubated 
with 1 ml of a 90 mM CNBr solution in 70% formic acid for 24 h, 
at room temperature. The solution was then diluted 10-fold with 
water and freeze-dried. 
2.4. Purification of the recombinant protein 
The CNBr treated material was applied to a reverse phase HPLC 
column (Vydac C4, 4.6 x 250ram) equilibrated in 0.1 M 
triethylamine adjusted to pH 3.2 with pure formic acid. A 60 min 
gradient of 0-40%0 acetonitrile at a flow rate of 1 ml/min was then 
applied. After freeze-drying, the purified protein was incubated in 
100/zl of pure ethanolamine for 30 rain at room temperature for 
deformylation [2] and then freeze-dried again. A desalting step was 
finally performed on a reverse phase HPLC column (Aquapore 
RP-300, 2.1 x 30 mm) using a TFA/CH3CN/H20 gradient system: 
5 min elution with 0.1%0 TFA (A) followed by a 10 min gradient of 
0-100%0 B in A (B: 70% CH3CN in A) at a flow rate of 0.5 ml/min. 
2.5. Biological assays 
Radioimmunoassays were carried out as previously described [3] 
using 3H-labelled toxin oe from Naja nigricollis [4] and Moe2-3 
monoclonal antibody [5]. Specific binding and affinity of fused and 
cleaved erabutoxins for acetylcholine r ceptor-rich membranes were 
determined from competition experiments [6] using 3H-labelled toxin 
oe. Native erabutoxin a was purified from Laticauda sem~fasciata [7]° 
The lethal dose (LDso) was determined by i.p. injections of purified 
cleaved protein in 20 g BALB/c mice. 
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3. RESULTS AND DISCUSSION 
3.1. Purification and characterization 
The hybrid possesses four methionine residues that 
are all located before the erabutoxin sequence and one 
of them was purposely located at position -1 of 
erabutoxin a by site directed mutagenesis [1]. Treat- 
ment with CNBr was therefore xpected to release the 
toxin moiety. Chromatography on the RP-column of 
the cleaved hybrid led to three main resolved com- 
ponents which were investigated for their ability to 
compete with a radioactive toxin in binding with a 
toxin-specific monoclonal antibody named M~2-3 [5]. 
Components 1 and 3 were recognized by the antibody 
and coeluted respectively with native erabutoxin and 
the hybrid. Component 1 was treated with 
ethanolamine [2], desalted and rechromatographed on 
RP-HPLC using a highly resolutive TEAF system [6]. 
Fig. 1 shows that recombinant erabutoxin (Ea,) 
coeluted on RP-HPLC and coelectrophoresed on
polyacrylamide g l with native erabutoxin a (Ean). In 
both cases, Ear appeared homogeneous. Approximate- 
ly 0.25 mg of Ea, was obtained from 3 mg hybrid. 
The amino acid compositions of the recombinant 
and native toxins were identical within the experimental 
error (Table I). In both cases however, the lie content 
was lower than expected from sequence data (Table II). 
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Fig. 1. Analysis of recombinant erabutoxin a by RP-HPLC and 
isoelectric focusing. Left, approximately 5/~g of native erabutoxin a 
and 5/~g of recombinant erabutoxin a were mixed and loaded onto 
a Vydac C4 column (250 × 4.6 ram) and eluted with a 60 min 
gradient of 0 -40% acetonitrile in 0.1% TFA at a flow rate of 
1 ml/min.  The detection was monitored at 210 nm. Right, native 
(Ea,) and recombinant (Ear) erabutoxin a were submitted to 
isoelectric focusing in a 8% polyacrylamide gel using a pH 3.5-10 
Amphol ine gradient as previously described [10]. About 20/Lg of 
protein were loaded in each lane. Gels were stained with 
Coomassie blue. 
Table I 
Amino acid compositions of native or recombinant erabutoxin a
Amino acid From sequence Native Recombinant 
analysis erabutoxin erabutoxin 
Asx 5 5.29 5.26 
Glx 8 8.69 8.72 
Ser 8 8.07 8.08 
Gly 5 5,25 5.34 
His 1 0.99 1.15 
Arg 3 2.81 2.77 
Thr 5 5.58 5.48 
Ala 0 0.07 0.15 
Pro 4 4.11 4.09 
Tyr 1 1.04 0.93 
Val 2 1.57 1.56 
Met 0 0.04 0.00 
lie 4 2.42 2.40 
Leu 1 0.97 1.13 
Phe 2 2.06 2.13 
Lys 4 4.03 3.95 
Cys 8 ND ND 
Trp 1 ND ND 
ND, not determined 
Table II 
Automated sequence analysis of the 50 first residues of recombinant 
erabutoxin a
Cycle Residue Amount  Cycle Residue Amount 
number assigned (pmol) number assigned (pmol) 
1 R 191 32 
2 I 1486 33 
3 C ND 34 
4 F 1089 35 
5 N 551 36 
6 H 219 37 
7 Q 710 38 
8 S 167 39 
9 S 216 40 
l0 Q 524 41 
11 P 484 42 
12 Q 416 43 
13 T 199 44 
14 T 207 45 
15 K 490 46 
16 T 191 47 
17 C ND 48 
18 S 62 49 
19 P 266 50 
20 G 270 51 
21 E 126 52 
22 S 55 53 
23 S 31 54 
24 C ND 55 
25 Y 96 56 
26 N 96 57 
27 K 148 58 
28 Q 114 59 
29 W 47 60 
30 S 25 61 
31 D 17 62 
F 65 
R 110 
G 36 
T 19 
I 71 
I 37 
E 12 
R 41 
G 43 
C ND 
G 32 
C ND 
P 11 
T 4 
V 8 
K 10 
P 8 
G 9 
I 10 
Analysis was carried out with about 1.5 nmol of reduced, S- 
pyridylethylated protein. ND, not quantitatively determined 
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This is probably due to a low yield on acid hydrolysis 
of the Ile-Ile bond [8], found at positions 36-37 in the 
toxin sequence. To assess that the four isoleucine 
residues were effectively present in Ea~, we submitted 
its reduced, S-pyridylethylated form to microsequenc- 
ing up to residue 50. As shown in Table II, the 
elucidated amino acid sequence of Ear is identical to 
that of Ea.. 
3.2. Structure 
We investigated the overall structure of Ear by 
analysing its far-ultraviolet circular dichroism 
characteristics (Fig. 2). Within experimental error, the 
spectra of Ea, and Ea~ superimposed, indicating that 
the dominant ~ sheet structure of erabutoxin [9] is 
preserved also in Ea~. 
We probed locally the structure of Ear in two ways. 
Firstly, we examined the antigenicity of Ear using 
M~2-3, a monoclonal ntibody which is highly specific 
for correctly folded neurotoxins and which recognizes 
a large domain encompassing the three adjacent loops 
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Fig. 2. Far-ultraviolet circular dichroism analysis of recombinant 
erabutoxin. Circular-dichroic spectra of native erabutoxin (1.9 x 
10 -5 M) (Ea,) or recombinant erabutoxin (1.7 x 10 -5 M) (Ear) were 
recorded in water. The cell path length was 0.05 cm. 
on the concave side of neurotoxins [5]. As shown on 
Fig. 3A, Ear and Ea, are equally potent at competing 
with 3H-labelled toxin ,~ for Mcr2-3. The epitope is 
therefore highly similar in both toxins. Secondly, we 
probed the AChoR binding site of Ear by determining 
in vitro its affinity for a suspension of membrane 
AChoR [6]. This experiment was of particular interest 
since the fused toxin had an affinity constant about 
70-fold lower than Ean for AChoR (Fig. 3B) and also 
was about 7-fold less toxic in vivo. As shown in 
Fig. 3B, Ear and Ean are strikingly equally potent at 
binding to AChoR. Furthermore, we found that they 
have the same toxicity to BALB/c mice (LDs0 -- 2 _+ 
0.5/zg/20 g mouse). These results support our former 
proposal that the low biological activity of fused toxin 
was due to the presence of the bulky protein A moiety 
and not to an incorrect folding of the toxin [1]. 
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Fig. 3. Biological assays. (A) Binding of all-labelled toxin o~ (3.4 nM, 
17 Ci/mmol) to the monoclonal antibody Ma2-3 (11.2 nM) in the 
presence of varying amounts of  either native erabutoxin a (3 x 10 -7 
to 3 x 10 -~° M) (Ea,) or recombinant erabutoxin a (1.5 x 10 -7 to 5 x 
10 -1° M) (Ea,). Incubation time was 24 h at 4°C. Toxin-antibody 
complexes were precipitated by polyethylene glycol [4]. (B) Inhibition 
binding curve of 3H-labelled toxin a (6 nM) to the acetylcholine 
receptor (3.8 nM) in the presence of varying amounts of either 
protein A-erabutoxin a hybrid 00  -6 to 5 x 10 -9 M), native 
erabutoxin a (10 -~ to 10 -t° M) (Ea,) or recombinant erabutoxin a
(10 -7 to l0 -10 M) (Ear). Incubation time was 6 h at 20°C. The 
mixtures were filtered through Millipore filters as previously 
described [6]. 
89 
Volume 266, number 1,2 FEBS LETTERS June 1990 
Altogether, our results indicate that the recombinant 
toxin is virtually identical with native erabutoxin a. 
This is the first report showing that a recombinant 
animal toxin has the same physicochemical and 
biological properties as the natural toxin. Since the 
recombinant toxin can be produced in the milligram 
range from the fused toxin, we now have in hand a 
well-suited system to prepare appropriate mutants for 
studying toxin-acetylcholine receptor interactions. 
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